Attached files

file filename
10-K - 10-K - SOLENO THERAPEUTICS INCslno-10k_20201231.htm
EX-32.1 - EX-32.1 - SOLENO THERAPEUTICS INCslno-ex321_7.htm
EX-31.2 - EX-31.2 - SOLENO THERAPEUTICS INCslno-ex312_8.htm
EX-31.1 - EX-31.1 - SOLENO THERAPEUTICS INCslno-ex311_6.htm
EX-23.1 - EX-23.1 - SOLENO THERAPEUTICS INCslno-ex231_9.htm
EX-21.1 - EX-21.1 - SOLENO THERAPEUTICS INCslno-ex211_10.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Soleno Therapeutics, Inc. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2020, as filed with the Securities and Exchange Commission (the “Report”), James Mackaness, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 3, 2021

 

/S/ JAMES MACKANESS

James Mackaness

Chief Financial Officer

(principal financial and accounting officer)